Get the Stockscreener App
2.30
2.37%
0.02
Actuate Therapeutics Inc stock is traded at $2.30, with a volume of 3,116.
It is up +2.37% in the last 24 hours and down -39.87% over the past month.
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
See More
Previous Close:
$2.32
Open:
$2.31
24h Volume:
3,116
Relative Volume:
0.04
Market Cap:
$53.46M
Revenue:
-
Net Income/Loss:
$-24.12M
P/E Ratio:
-1.9016
EPS:
-1.2095
Net Cash Flow:
$-20.24M
1W Performance:
-5.00%
1M Performance:
-39.87%
6M Performance:
-65.53%
1Y Performance:
-70.31%
1-Day Range:
$2.295
$2.31
1-Week Range:
$2.15
$2.70
52-Week Range:
$2.15
$11.99
Actuate Therapeutics Inc Stock (ACTU) Company Profile
Name
Actuate Therapeutics Inc
Sector
Industry
Phone
847-986-4190
Address
1751 RIVER RUN, FORT WORTH
Compare ACTU vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACTU
Actuate Therapeutics Inc
|
2.30 | 53.92M | 0 | -24.12M | -20.24M | -1.2095 |
VRTX
Vertex Pharmaceuticals Inc
|
451.39 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
754.55 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
329.82 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
687.64 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.26 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Actuate Therapeutics Inc Stock (ACTU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-26-25 | Initiated | B. Riley Securities | Buy |
| Apr-22-25 | Initiated | Craig Hallum | Buy |
| Mar-17-25 | Initiated | H.C. Wainwright | Buy |
Actuate Therapeutics Inc Stock (ACTU) Latest News
Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers - Finviz
Aug Levels: Is Actuate Therapeutics Inc benefiting from innovation trends2026 Retail & Safe Entry Point Identification - baoquankhu1.vn
Aug Outlook: Can Actuate Therapeutics Inc scale operations efficiently2026 Selloffs & Entry Point Confirmation Signals - baoquankhu1.vn
Actuate Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | ACTU | US0050831009 - marketscreener.com
Aug Shorts: Can Actuate Therapeutics Inc outperform under higher oil pricesWeekly Trade Summary & Reliable Momentum Entry Alerts - baoquankhu1.vn
Voss Capital LP Boosts Stake in Actuate Therapeutics, Inc. $ACTU - MarketBeat
How Much Upside is Left in Actuate Therapeutics, Inc. (ACTU)? Wall Street Analysts Think 214.06% - MSN
Actuate Therapeutics Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors - Bitget
RSI Check: Is Actuate Therapeutics Inc stock showing strong momentumWeekly Investment Recap & Safe Capital Growth Stock Tips - baoquankhu1.vn
Actuate Therapeutics files $250M mixed securities shelf - MSN
Will Actuate Therapeutics Inc. stock gain from lower inflationPortfolio Update Summary & Reliable Price Breakout Signals - Naître et grandir
Actuate Therapeutics (NASDAQ:ACTU) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Activity Recap: How buybacks impact Actuate Therapeutics Inc. stock valueMarket Weekly Review & Safe Capital Allocation Plans - Naître et grandir
Actuate Therapeutics to Present at The Citizens Life Sciences Conference - Bitget
Actuate Therapeutics, Inc. Announces Presentation at Citizens Life Sciences Conference in Miami Beach - Quiver Quantitative
Actuate Therapeutics to Present at The Citizens Life Sciences Conference - GlobeNewswire Inc.
ACTUActuate Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
ACTU Technical Analysis & ETF Price Forecast - Intellectia AI
Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - The Manila Times
Actuate Therapeutics, Inc. to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026 - Quiver Quantitative
ACTU Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Is Actuate Therapeutics Inc. stock undervalued right nowMarket Performance Report & Daily Stock Trend Watchlist - mfd.ru
Actuate Therapeutics (NASDAQ:ACTU) Rating Increased to Hold at Wall Street Zen - Defense World
ACTU PE Ratio & Valuation, Is ACTU Overvalued - Intellectia AI
Is Actuate Therapeutics Inc. stock risky to hold nowPortfolio Update Report & Technical Confirmation Trade Alerts - mfd.ru
A | Will SIMAU announce a stock splitJuly 2025 Trends & Stepwise Entry and Exit Trade Signals - mfd.ru
Actuate Therapeutics (NASDAQ:ACTU) Shares Down 3.6%Here's What Happened - MarketBeat
What is the long term forecast for GATES GROUP Inc. stockJuly 2025 Selloffs & AI Enhanced Trading Signals - baoquankhu1.vn
Published on: 2026-02-07 16:03:44 - baoquankhu1.vn
Actuate Therapeutics registers 1.33M shares for resale by investors - MSN
Patterns Watch: Is Actuate Therapeutics Inc benefiting from innovation trendsJuly 2025 Sentiment & Risk Managed Investment Entry Signals - baoquankhu1.vn
Decliners Report: Is Actuate Therapeutics Inc benefiting from innovation trendsBreakout Watch & Daily Profit Maximizing Tips - baoquankhu1.vn
Becoming A Backbone Therapy: Lessons Learned With Actuate Therapeutics - Clinical Leader
Actuate Therapeutics, Inc.'s (NASDAQ:ACTU) market cap dropped US$13m last week; Private equity firms bore the brunt - Yahoo Finance
Sectors Review: Will Actuate Therapeutics Inc stock benefit from M AJuly 2025 Trade Ideas & Capital Efficiency Focused Strategies - baoquankhu1.vn
Actuate Therapeutics plans phase 1/2 trial of oral cancer drug - Investing.com Nigeria
Aug EndMonth: Whats the beta of PHGE stockJuly 2025 Chart Watch & Verified Entry Point Detection - baoquankhu1.vn
Actuate Therapeutics, Inc. Announces Initiation of Phase 1/2 Clinical Trial for Elraglusib Tablet in Advanced Cancers - Quiver Quantitative
Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers - manilatimes.net
Actuate Therapeutics Announces Plans to Expand Clinical - GlobeNewswire
Actuate Therapeutics, Inc. (NASDAQ:ACTU) Sees Significant Growth in Short Interest - MarketBeat
Risk Report: Why is VNCE stock going down2025 Technical Patterns & Detailed Earnings Play Strategies - baoquankhu1.vn
Merger Talk: Is Actuate Therapeutics Inc stock undervalued right nowInflation Watch & Fast Moving Stock Trade Plans - baoquankhu1.vn
Actuate Therapeutics (NASDAQ:ACTU) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Actuate Therapeutics (NASDAQ:ACTU) Downgraded by Wall Street Zen to “Sell” - Defense World
Actuate Therapeutics, Inc. (ACTU) Receives a Buy from Craig-Hallum - The Globe and Mail
Market Wrap: Does Actuate Therapeutics Inc have consistent dividend growth2025 Price Targets & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Published on: 2026-01-16 10:23:54 - baoquankhu1.vn
Published on: 2026-01-16 07:35:07 - baoquankhu1.vn
H.C. Wainwright reiterates Buy rating on Actuate Therapeutics stock at $20 - Investing.com UK
Actuate Therapeutics Inc Stock (ACTU) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.99%
3.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):